期刊文献+

EZH2蛋白在乳腺癌中的表达及其临床意义 被引量:6

THE EXPRESSION AND CLINIC SIGNIFICANCE OF EZH2 PROTEIN IN BREAST CANCER
下载PDF
导出
摘要 目的研究EZH2蛋白在乳腺癌中的表达情况及其临床意义。方法通过免疫组化SP法检测EZH2蛋白在40例乳腺癌伴有淋巴结转移、63例乳腺癌不伴淋巴结转移及31例乳腺增生组织中的表达情况。结果从乳腺增生-乳腺癌不伴淋巴结转移-乳腺癌伴有淋巴结转移,EZH2蛋白阳性表达率依次增强,分别为22.58%、52.38%、75.00%。EZH2与患者乳腺癌及淋巴结转移呈显著关系(p<0.01)。结论 EZH2蛋白在乳腺癌中高表达,尤其是在乳腺癌伴有淋巴结转移中的表达显著提高,提示EZH2的过表达与乳腺癌进展及不良预后有关。 Objective This study is to explore the expression and clinic significance of EZH2 (enhancer of zeste homolog2) protein in breast cancer. Methods The expressions of EZH2 protein in 40breast cancer with lymph node metasta- sis tissues, 63breast cancer without lymph node metastasis tissues,31 hyperplasia of mammary glands tissues by SP immunohis- toehemical method. Results The rate of expressions of EZI-I2 protein in 40breast cancer with lymph node metastasis tissues, 63breast cancer without lymph node metastasis tissues,31 hyperplasia of mammary glands tissues were 75.00% (30/40) ,52. 38% (33/63) ,22.58% (7/31)respectively. The expressions of EZH2 protein in cancer tissions was higher than that in hy- perplasia of mammary glands tissues(p 〈0. 01 ). Conclusion The abnormal expressions of EZH2 are closely associated with the development of breast cancer,which may play an important role in the development of breast cancer. The overexpressions of EZH2 is correlated to breast cancer progression and poor prognosis.
出处 《现代医院》 2013年第7期63-64,共2页 Modern Hospitals
关键词 乳腺癌 EZH2 免疫组化 Breast cancer, EZH2, immunohistochemical
  • 相关文献

参考文献16

  • 1南润玲,尚培中,王铁山.乳腺癌易感基因BRCA1的研究进展[J].实用医学杂志,2011,27(12):2284-2286. 被引量:14
  • 2KARANIKOLAS B D,FIGUEIREDO M L,WU L.Polycomb group protein enhancer of zeste2is an oncogene that promotes the neo-plastic transformation of a benign prostatic epithelial cell line[J].Mol Cancer Res,2009,7:1456-1465.
  • 3BREUER R H,SNIJDERS P J,SMIT E F,et al.Increased expres-sion of the EZH2polycomb group gene in BMI-l-positive neo-plastic cells during bronchial carcinogenesis[J].Neoplasia,2004,6(6):736-743.
  • 4WEIKERT S,CHRISTOPH F,KOLLERMANN J,et al.Expression levels of the EZH2polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas[J].Int J Mol Med,2005,16(2):349-353.
  • 5刘筱青.EZH2基因在胰腺导管腺癌的表达及与E钙黏附蛋白相关性研究[J].中国现代医生,2011,49(13):57-58. 被引量:3
  • 6ARISAN S,BUYUKTUNCER E D,PALAVAN-UNSAL N,et al.Increased expression of EZH2,a polycomb group protein,in blad-der carcinoma[J].Urol Int,2005,75(3):252-257.
  • 7CARDOSO C,MIGNON C,HETET G,et al.The human EZH2 gene:genomic organization and revised mapping in7q35within the critical region for malignant myeloid disorders[J].Eur J Hum Genet,2000,8(3):174-180.
  • 8KLEER C G,CAO Q,VARAMBALLY S,et al.EZH2is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells[J].Proc Natl Acad Sci USA,2003,100(20):11606-11611.
  • 9RAAPHORST F M,MEIJER C J,FIERET E,et al.Poorly differen-tiated breast carcinoma is associated with increased expression of human polycomb group EZH2gene[J].Neoplasia,2003,5(6):481-488.
  • 10VARAMBALLY S,DHANASEKARAN S M,ZHOU M,et al.The polycomb grop protein EZH2is involved inprogression of prostate cancer[J].Nature,2002,419(6907):624-629.

二级参考文献57

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2刘阳,王立国.保乳手术治疗早期乳腺癌的临床分析[J].实用医学杂志,2006,22(20):2411-2412. 被引量:28
  • 3刘静,赵浩亮.1,25二羟维生素D_3与三苯氧胺对乳腺癌细胞生长及凋亡的影响[J].中国药物与临床,2007,7(7):534-535. 被引量:3
  • 4Jemal A,Siegel R,Ward E,et aL Cancer statistics,2008[J]. CA Cancer J Clin, 2008,58 ( 2 ) : 71-96.
  • 5Cao Q,Yu J,Dhanasekaran SM,et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer[J]. Oncogene,2008,27 (58) : 7274-7284.
  • 6Mimorl K, Ogawa K, Okamoto M, et al. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases[J]. Eur J Surg Oncol, 2005,31 (4) : 376-380.
  • 7Chen H,Tu SW,Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer[J].J Biol Chem,2005,280(23):22437-22444.
  • 8Su IH,Basavaraj A,Krutchinsky AN,et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement[J]. Nat Immunol,2003,4(2) : 124-131.
  • 9Cardoso C,Mignon C,Hetet G,et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders[J]. Eur J Hum Genet,2000,8 (3) : 174-180.
  • 10Peppone L J, Huston A J, Reid M E, et al. The effect of various vitamin D supplementation regimens in breast cancer patients [J]. Breast Cancer Res Treat, 2011,127 (1) : 171-177.

共引文献28

同被引文献34

  • 1Kennecke H,Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes[J]. J Clin Oncol, 2010,28(20): 3271-3277.
  • 2Albadine R,Wang W,Brownlee NA,et al. Topoisomerase II c~ status in renal medullary carcinoma:immuno-expression and gene copy alterations of a potential target of therapy [J]. J Urol, 2009, 182(2) :735-740.
  • 3Coss A, Tosetto M, Fox E J, et al. Increased topoisomerase Ilalpha expression in coloreetal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis[J]. Cancer Lett, 2009,276(2):228-238.
  • 4Rody A,Karn T,Ruckh~iberle E,et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer [J]. Breast Cancer Res Treat, 2009,113 (3) :457-466.
  • 5Milde-Langosch K,Karn T,Miiller V,et al. Validity of the proliferation markers Ki67,TOP2A,and RacGAP1 in molecular subgroups of breast cancer [J]. Cancer Res Treat, 2013,137( 1 ) : 57-67.
  • 6Xiao Yao,Hua Jiang,Cuizhen Zhang,Huamao Wang,Lin Yang,Yongfeng Yu,Junming Yu,Bizhi Shi,Zhijun Shen,Huiping Gao,Zhiwei Chen,Shujun Tian,Shun Lu,Zonghai Li,Jianren Gu.Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer[J].Biomarkers.2010(2)
  • 7王秀华,王学中,贺洪亮.床边简易中心静脉压测定的影响因素及护理对策[J].中国医药指南(学术版),2008,6(19):166-167. 被引量:6
  • 8孙旸,李立安,宋磊,朱守兰.拓扑异构酶Ⅱα和Ki-67表达与子宫肉瘤预后的相关性研究[J].解放军医学杂志,2008,33(11):1325-1328. 被引量:6
  • 9马怡晖,郑湘玉,李惠翔.乳腺黏液癌与普通型乳腺浸润性导管癌临床病理特征和ER、PR、P53、C-erbB-2、Ki-67表达差异分析[J].中华临床医师杂志(电子版),2012,6(14):3909-3913. 被引量:10
  • 10周晓雷,张晓东,叶丽虹.DKK-1通过上调nm23表达抑制乳腺癌细胞迁移[J].中国生物化学与分子生物学报,2010,26(2):164-169. 被引量:7

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部